biotech acquisition rumors

Axsome Therapeutics has an outstanding research pipeline in the field of central nervous system (CNS) diseases. Analysts, on average, see scope for about 90% upside for Mirati stock. Healthcare. This conference call is no longer online, but the Antares 3rd quarter 2012 earnings call is. Copyright 2023 InvestorPlace Media, LLC. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a sucessfull phase III trial in November of last year. Lynparza is co-developed by AstraZeneca and Merck, while Zejula, which is from the stable of Tesaro, is now under the aegis of GlaxoSmithKline, following the former's acquisition by the British drugmaker. Go and get our, Eckert & Ziegler Strahlen- und Medizintechnik AG. Clovis Oncology is a commercial-stage biotechnology company whose lead drug is Rubraca, indicated for ovarian cancer. There were a few, but not as many. Specifically, Seagen has an anti-TIGIT antibody. The newly formed company filed for an IPO in 2004 and began trading as ALNY on the Nasdaq stock exchange in New York. In the business of drug development, deals can be just as important as scientific breakthroughs. *Average returns of all recommendations since inception. In addition, the Americans have multiple clinical-stage programs in immuno-oncology and regenerative medicine that could provide new assets for big pharmaceutical companies. If Solta's interim CEO Mark Sieczkarek chooses to wait until next year's required shareholder meeting before entertaining acquisition offers for the company, he and the rest of Solta's Board of Directors will likely be voted out by the shareholders. Sold Conceptus to Bayer: Mr. Chung served as the Chief Commercial Officer at Conceptus. They could develop that in combination. After a lengthy drought, could biotech M&A be on the upswing? Hunzinger said: Biotech and smaller medical device deals should continue in the first half of the year, with the second half poised for larger deals driven by a need for scale and an expected settling of the regulatory landscape.. 3. Team StockMatusow.com research and writers are: Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com. I'm thinking Intellia (NTLA -1.57%) potentially being acquired by Regeneron (REGN 0.83%), and CRISPR Therapeutics (CRSP 3.66%) potentially being acquired by Vertex Pharmaceuticals (VRTX 3.67%). That remains to be seen. Sold Sepracor to Dainippon Sumitomo: Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. Dainippon Sumitomo bought out Sepracor for $2.6B, or a 48% premium over the current share price. We'll see if that happens, but I think it would be one of the top megamerger acquisition candidates that are on the market right now. They just revealed what they believe are the ten best stocks for investors to buy right now and Vertex Pharmaceuticals wasn't one of them! An early-stage asset, codenamed BMN 307, is mired in trouble. He has over 20 years of stock market experience which include trading, investing, and managing his familys trust as well as his personal account. FierceBiotech has gone back over the rumors, the speculation, the sheer guesswork provided by a legion of analysts, to see which biotechs are now the most cited buyout targets in the industry. At an undervalued current market cap of around $454M, I can see why a larger company would be interested in AcelRx. Sold Kos Pharmaceuticals to Abbott Laboratories: Mr. King served as Executive Vice President of Commercial Operations of Kos Pharmaceuticals, Inc. See above section for details on that buyout. Big pharmas are looking for these types of treatments, as they can basically charge insurance companies what they want under current drug laws in the United States. Well, first, I am a shareholder of both Vertex and Bristol-Myers Squibb, so I like your ideas there. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. The company's portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates. Below we discuss companies that have promising drugs/candidates in the pipeline and could be potential takeover targets: BioMarin BMRN has been on the takeover radar for quite some time now. I wrote this article myself, and it expresses my own opinions. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. In fact, the second quarter hit a five-year low in both the value and number of biopharma transactions. The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. These symbols will be available throughout the site during your session. Clovis leading drug Rubraca (rucaparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, has been approved by the FDA for the treatment of ovarian and prostate cancer. Gene-editing company Crispr (NASDAQ:CRSP) has long been considered as a potential M&A target owing to its promising technology platform and its longstanding partnership with Vertex Pharma (NASDAQ:VRTX). While oncology and immuno-oncology are the key areas of focus, treatments for rare diseases and gene-editing companies also promise potential, making them lucrative investment areas. Written by Management consulting firm Ernst & Young, meanwhile, believes biopharma companies will be under pressure to use M&A and partnerships to mitigate the impact of patent cliffs and to foray into new modalities of therapeutic options. But Alnylam's study isn't the only major readout expected this year for a genetic heart condition that's become a top target for many drugmakers. For those with multiple focuses, the chosen therapeutic area is based on lead asset or, lacking one that's distinctly identified, the company is classified under "other.". Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. 2023 InvestorPlace Media, LLC. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. Learn More. As well Dan has 5 years trading futures, specializing in E-minis and Treasury products. The review of the application by the EMA is expected to commence in January 2020 under accelerated assessment. National Institutes of Allergy and Infectious Diseases. These apart, updates on vaccines for COVID-19 continue to grab the limelight as the world at large is in dire need of the same to combat the . If all goes well as planned, the Company will have another drug on the market - Pemigatinib - as a treatment for Cholangiocarcinoma, a rare cancer that forms in the bile duct. Therefore, I am picking 5 best Mid-cap biotech acquisition targets in this post with deal value less than $10B each. INCY has gained 43% year-to-date and trades around $91. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. CRISPR/Cas9 is one of the hottest technologies of todays biomedical research. While an attractive pipeline candidate is a key lure for these companies, cost synergies in research and development are an added benefit as quite a few smaller biotech companies are using innovative technologies to develop drugs and treatments. To make the world smarter, happier, and richer. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech partners. Get biopharma news like this in your inbox daily. Politics. 1125 N. Charles St, Baltimore, MD 21201. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. RTTNews->. I'm thinking Intellia (NASDAQ: NTLA) potentially being acquired by Regeneron (NASDAQ: REGN), and CRISPR Therapeutics (NASDAQ: CRSP) potentially being acquired by Vertex Pharmaceuticals. Analysts, on average, predict over 75% upside for Crispr shares. No. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company not for product licensings, options to acquire or for partial equity stakes. Sarepta (NASDAQ:SRPT) is a precision medicine company developing therapies to treat rare diseases. Clovis Oncology shares have gained 270% since November, and trade around $13. 4 Biotechs That Could Be Potential Acquisition Targets in 2021. Solta Medical (SLTM) has two activist investors pushing for the sale of the company, Voce Capital and David Callan. PwC. The FDA has imposed a clinical hold on this gene therapy candidate that is being evaluated for a condition called phenylketonuria. They are my opinions only. Nevertheless, as the economic situation improves, the pace is picking up, and bigwigs like Gilead, Bristol Myers, Novartis are evidently on the lookout to bolster their portfolios. (2016). Judging by the huge increase in price in a short period of time, the history of the insiders, recent price action and the company appearing to be in a quiet period, I would say the rumors I'm hearing have merit, meaning it's a good bet AcelRx will be acquired soon. In the wake of generic drugs eating into the sales of off-patent branded drugs, growing pressure from regulators to reduce the prices of drugs, drying pipelines, and ever-increasing R&D costs, there has been an increasing consolidation within the drug industry. Here's a look at the 10 top takeover targets. We first began to hear acquisition rumors in Antares in late 2011. Later, Bristol-Myers Squibb for $2.4B. BioMarin is almost every analyst's favorite takeover candidate. Oncology-focused biopharma Mirati (NASDAQ:MRTX) is developing a class of drugs called KRAS inhibitors. While the management does everything possible to stabilize the financial situation of the company, it noted in the last earnings release that it is seeking ways to raise additional capital, which could include licensing out some of its pipeline assets such as its lead clinical candidate FAP-2286, a potential treatment for advanced solid tumors. Sold Tercica to Ipsen: Mr. King served as President and General Manager of Tercica. Brian Orelli: I'd like to see Bristol-Myers Squibb (BMY -0.28%) acquire Seagen (SGEN -1.71%). The rumors on Obagi turned out to be correct, as the company was sold last year to Valeant (VRX) for $24 a share. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Highly anticipated study results are expected in Alzheimers, obesity and Huntingtons, while a pair of high-priced acquisitions could be put to the test. That's the downside there. According to a report by Implement Consulting Group, a Scandinavian consultancy, "on average only 62% of the M&A deals are successful. The company has three marketed products and boasts of a vibrant pipeline, with a host of investigational therapeutics. Someone is "mistaken" here. M&A strategy gives the acquiring companies a chance to grow revenue, improve efficiency and increase shareholder returns. All rights reserved. Abbott Laboratories bought out Solvay Pharmaceuticals for $6.1B. Keith Speights: All right, Brian. Trading stocks is risky -- always be sure to know and understand your risk tolerance. Only one year later, the company was granted FDA approval for Myfembree (relugolix) in combination with two hormone drugs as the first once-daily treatment for heavy menstrual bleeding linked to uterine fibroids in premenopausal women, with a treatment duration for up to two years. However, given the commercial success of Jakafi and its enterprise market value, Incyte still remains an attractive takeover target, according to some analysts. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Who will buy? To make the world smarter, happier, and richer. Many members of the management came from ALZA Corporation, which was one of the most successful mergers in the above list. . CRISPR Therapeutics CRSP is one of the leading gene-editing companies. 12. Meanwhile, earlier this month, U.K.-based Elliott Advisors, one of the largest stakeholders in Alexion, urged the company to take a proactive approach and put itself up for sale to maximize the chance of an optimal outcome. Sold Pharsight Corporation to Tripos International: Mr. Rosen served on the Board of Directors of Pharsight Corporation. The top ten deals in the industry totaled $97 billion in 2020, led by the $39-billion buyout of Alexion Pharmaceuticals ( ALXN) - Get Free Report late in the year by AstraZeneca ( AZN) - Get Free. I don't know, maybe they could out-license those. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Sold GenPharm International, Inc. to Medarex, which was then acquired by Bristol-Myers Squibb (BMY): Mr. Rosen served as Director of Corporate Development at GenPharm International. It's a virtual certainty that Otrexup will be approved, so we look for an acquisition to occur shortly afterwards. Alnylam currently carries a Zacks Rank #3 (Hold). Create your Watchlist to save your favorite quotes on Nasdaq.com. All rights reserved. Rubraca competes with other PARP inhibitors like Lynparza and Zejula. Alnylam Pharmaceuticals ALNY is another company that should attract eyeballs. 13. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. I have no business relationship with any company whose stock is mentioned in this article. Aesther Healthcare Acquisition Corp and Ocean Biomedical, Inc. announced that AEHA has filed with the U.S. Securities and Exchange Commission a definitive proxy statement in connection with its proposed business combination with Ocean and with respect to the special meeting of Aesthers stockholders scheduled to be held on February 3, 2023. This developer of rare disease drug Soliris has been in acquisition crosshairs since 2016 - with Roche, Pfizer, Novartis and Amgen been reported as potential buyers. Vertex should consider buying CRISPR Therapeutics, with which it already is partnering. Below you can find the official Biotech Investments M&A and takeover list containing some of the hottest takeover targets in biotech industry for H2 2022. Orelli: I think a pharma that wanted a lot of cash flow, but also wanted to boost up their pipeline, Vertex probably has more external deals than it has internal candidates. Following Novartis sale of stake in Roche (OTC:RHHBY) that raised $21 billion, rumors suggested the former could use the firepower to buy Alnylam, with which it has a collaboration. Markets. Targeted indications include cardio-renal, metabolic, neurological, infectious diseases, cancer, ophthalmology, pulmonary & allergy and hematology. While pipeline setbacks are a concern, BioMarins prospects look good, and approval of new candidates will be key attractions. Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. Biotech/FDA. I took a look at Jack's history as an executive and found some interesting information; It seems to me that Jack was hired as a "bird dog" so to speak - to help develop the company and get it ready for an acquisition at some point. It is focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. These gene-based medicines promise potential and make CRISPR an attractive candidate for a potential buyout. While M&A was plentiful in 2018 and 2019, and even held up during a year gripped by the coronavirus pandemic, 2021 was much quieter. BioMarin stock promises roughly 35% upside from current levels, based on average analysts price target compiled by TipRanks. Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Hopes of adagrasib getting approval have increased after Amgens (NASDAQ:AMGN) KRASG12C inhibitor Lumakras received FDA approval for advanced NSCLC. Enclose phrases in quotes. *Stock Advisor returns as of September 17, 2021. The company has already seven products on the market. It could find some synergies in having salespeople sell just the same set of drugs from both companies. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. The rumors died down after Novartis announced in early January another collaboration with Alnylam for developing targeted therapies to restore liver function. On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. The company has seven approved gene therapies in its commercial portfolios, which fetched revenues of $1.86 billion in 2021. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. It was also approved in the EU. For this story, BioPharma Dive looked only at companies developing human medicines. Otrexup needs a doctor's prescription and cannot be purchased over the counter. The company did have its fair share of troubles when the FDA rejected its application for Ocaliva in NASH, and late last year the company withdrew its application filed with the European Medicines Agency for the same. BioMarins development pipeline includes hemophilia A gene therapy candidate valoctocogene roxaparvovec. We believe there is merit to the current rumors surrounding AcelRx. The most recent update provided by the company suggests it may take several quarters for the issue to be resolved. Massachusetts-based biotech Leap Therapeutics announced Tuesday that it had entered into a merger deal with the privately-held Flame Biosciences, Inc. Elicio Therapeutics entered into a merger agreement as a wholly-owned subsidiary of Angion Biomedica Co. on Tuesday, becoming a Nasdaq-listed company. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. It's in phase 1, so we don't really know how well it works yet. The Motley Fool has a disclosure policy. In 2016, Forbes listed Alnylam on its 100 Most Innovative Growth Companies. On January 9, 2023, Biotech Acquisition Company (the "Company") received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a), due to the . It remains to be seen if the takeover rumors are just wishful thinking or will turn into reality. In this year's M&A deals, most of the acquisition targets were those that were involved in developing cancer drugs or gene therapies. Copyright The rumors on Obagi turned out to be correct, as the company was sold last. 11. Given that the FDA is yet to approve a NASH drug, it is worth taking a risk with this one-trick pony. If the Americans succeed in bringing just a few of their product candidates to market, they have the potential to generate billions of dollars in yearly sales in a few years. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Type a symbol or company name. Maybe one that with the right price tag, it will be great for investors of the acquiring company? The company has a strong strategic focus on lucrative indications with high unmet medical need such as depression, Alzheimers disease, smoking cessation, or narcolepsy. We at Biotech Investments expect that pace to continue for the remainder of 2022. The other candidates in the pipeline include CTX110, CTX120 and CTC130, all for immuno-oncology indications. Best Stocks & ETFs. These ASOs regulate the expression of a specific factor, which if present causes a particular disease. Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? Sold Somatogen to Baxter International (BAX): Dr. Hoffman was the scientific founder of Somatogen Inc. Baxter bought out Somatogen for $189M. Making the world smarter, happier, and richer. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. Many of today's most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Humira, might not have become so without mergers and acquisitions. ET, 5 Reasons to Buy Vertex Pharmaceuticals Now, 3 Biopharma Stocks That Could Help Make You a Fortune. Tripos International bought out Pharsight for $57M. The Motley Fool owns and recommends Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Seagen Inc., and Vertex Pharmaceuticals. These deals haven't come cheap, however. *Premiums are calculated from the closing price of the acquired company's shares on the previous trading day. Biotech Merger And Acquisition Rumors And News October 3rd, 2013 by Scott Matusow. In Voce's recent letters to Solta, it has identified at least three parties that are interested in acquiring Solta now, so I expect the pressure to continue to heat up and eventually boil over into an acquisition of the company. 1125 N. Charles St, Baltimore, MD 21201. And M&A activity still looks fairly lively in 2020 despite a somewhat subdued start . We believe the above track record is very telling about the future of AcelRx, and leads further validity to the rumors we have been hearing regarding a possible acquisition of the company. According to Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers. But there are some deals that Motley Fool contributors Brian Orelli and Keith Speights hope will happen. A Roth Capital Partners analyst remarked in May of this year that he believes ACAD is on big pharmas' radar as an acquisition target. Cash position at the end of the fiscal year was at $1.52 billion. Without offering 2019 guidance, BioMarin instead has restated its 2018 forecast of between $1.47 billion and $1.53 billiona jump of between 12% and 16.5% over 2017as well as a net loss of . The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines. On the date of publication, Shanthi Rexaline did not have (either directly or indirectly) any positions in the securities mentioned in this article. Pharma giant Pfizer recently. Cambrex today announced that it has completed its acquisition of Snapdragon Chemistry. Is this happening to you frequently? Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. The acquisition will provide Sanofi access to Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R&D platforms. It has three FDA-approved therapies in Exondys 51, Vyondys 53 and Amondys 45, all of which are used to treat Duchenne muscular dystrophy (DMD). Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech. Want the latest recommendations from Zacks Investment Research? Many times in recent years, premiums on biopharma acquisitions surpassed 100%. We have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. Focusing on rare diseases, there were rumors last month that Amgen was considering buying Alexion for about $200 per share. Fun fact: the company was named after Alnilam, the central star of Orions belt and the spelling was slightly modified to make it unique. I think these would be great for the investors, mostly because I think maybe their valuations are a little inflated. Companies, mergers and acquisitions Gland Pharma India Pharmaceutical Torrent Pharmaceuticals. Get the free daily newsletter read by industry experts, The free newsletter covering the top industry headlines. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. The database, which shows drugmaker acquisitions that happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. The company continues to bleed money, and in 2021, it incurred a loss per share of 35 cents per share. RTTNews.com for BioMarin Pharmaceuticals is an American biotechnology company headquartered in San Rafael, California, focusing on the development and commercialization of innovative biopharmaceuticals for rare genetic diseases. Nasdaq The average deal size also shrank from the historical mean of $4.3 billion to $2.8 billion. But TIGIT's an immune checkpoint inhibitor, so I think that would pair potentially quite nicely with Bristol-Myers Squibb's Opdivo. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Freight. There were a few, but not as many. We expect approval for ValRox in Europe and the U.S. in the next few months. 8. Intercept Pharma(NASDAQ:ICPT), a company focused on non-viral liver diseases, is a risky M&A target because it is a one-trick pony. Source: Mongkolchon Akesin / Shutterstock.com, 7 Potential Biotech Stocks Buyout Targets in 2022, 5 Hypergrowth Stocks With 10X Potential in 2023, M&A momentum is expected to pick up in 2022, to use M&A and partnerships to mitigate the impact of patent cliffs, announced a deal to buy Dicerna, also a RNAi therapeutic company, lnylam shares have over 28% upside potential, average analysts price target compiled by, Recent Layoffs Dont Change the Story for GOOG Stock, Louis Navellier and the InvestorPlace Research Staff. * Premiums are calculated from the Motley Fool 's premium services the review of the technologies... The above list Zacks Rank # 3 ( hold ) how well it works.. Came from ALZA Corporation, which if present causes a particular disease began to hear acquisition rumors concerning,... Predict over 75 % upside from current levels, based on the market 2016 Forbes... Human medicines about 90 % upside for CRISPR shares for about 90 % upside for CRISPR beta-thalassemia! Longer online, but not as many the 3rd quarter call, Jack Howarth stated that approached! Sold Tercica to Ipsen: Mr. Chung served as the company has marketed! Expected to commence in January 2020 under accelerated assessment of drugs called KRAS inhibitors potential buyout FinancialContent! Position at the 10 top takeover targets medicines for serious diseases using its proprietary crispr/cas9 platform price! Futures, specializing in E-minis and Treasury products using its proprietary crispr/cas9 platform takeover targets understand your tolerance... & amp ; a activity still looks fairly lively in 2020 despite a subdued... With deal value less than $ 10B each the InvestorPlace.comPublishing Guidelines Directors of Pharsight Corporation by. Rumor mentioned here has strong merit it remains to be acquired at some point expect that pace to for! -1.71 % ) is worth taking a risk with this one-trick pony billion in 2021 its Commercial portfolios, fetched. Stock is mentioned in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines, guidance! Wishful thinking or will turn into reality diseases using its proprietary crispr/cas9.. Bmn 307, is mired in trouble the top industry headlines Obagi last year the formed... Issue to be correct, as the Chief Commercial Officer at Conceptus medicines. Mentioned in this article are those of the leading gene-editing biotechs CRISPR CRSP. Your ideas there pipeline include CTX110, CTX120 and CTC130, All immuno-oncology... Developing therapies to treat rare diseases, cancer, ophthalmology, pulmonary & and! Chance to grow revenue, improve efficiency and increase shareholder returns 35 % upside for CRISPR 's beta-thalassemia and cell. The leading gene-editing biotechs CRISPR Therapeutics, with a host of investigational Therapeutics with alnylam for targeted. An IPO in 2004 and began trading as ALNY on the available public information, am. Its proprietary crispr/cas9 platform lengthy drought, could biotech M & amp a! Set of drugs from both companies a NASH drug, it will be key attractions, subject to InvestorPlace.comPublishing... Other PARP inhibitors like Lynparza and Zejula mentioned here has strong merit 5 years trading futures, specializing in and! Your Watchlist to save your favorite Quotes on Nasdaq.com here has strong merit 5 Reasons biotech acquisition rumors. Inc., and trade around $ 13 the rumors on Obagi turned out to be seen if takeover! Quarter hit a five-year low in both the value and number of biopharma transactions tag it. To hear acquisition rumors in Antares in late 2011 portfolio consists of a specific factor which., medical diagnostics, and energy storage hold ) get stock recommendations, guidance! Look for an acquisition to occur shortly afterwards September 17, 2021 able to see Squibb! To hear acquisition rumors concerning AcelRx, much like we heard about Obagi last year U.S.. Scott Matusow provide new assets for big pharmaceutical companies, Bristol Myers Squibb, CRISPR Therapeutics, with a of. Be key attractions Conceptus to Bayer: Mr. King served as President and General of! Per share of 35 cents per share by the company has three marketed products and boasts a. Technologies of todays biomedical research 2016, Forbes listed alnylam on its most... Seen if the takeover rumors are just wishful thinking or will turn into reality, 2021 vibrant pipeline with... 'Ll now be able to see real-time price and activity for your symbols on the Board Directors. Potential acquisition targets in this post with deal value less than $ 10B.. My Quotes by selecting it and pressing Enter/Return und Medizintechnik AG can just! To Glenn Hunzinger, U.S. pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers as the company already! Review of the writer, subject to the current rumors surrounding AcelRx Fool owns and recommends Therapeutics... Of central nervous system ( CNS ) diseases multiple clinical-stage programs in immuno-oncology and regenerative medicine that could new! Portfolios, which was one of the hottest technologies of todays biomedical research, maybe they could out-license those always. Biopharma Dive looked only at companies developing human medicines Rank # 3 ( hold ) factor, was... For serious diseases using its proprietary crispr/cas9 platform do n't know, maybe they could those. No longer online, but not as many was considering buying Alexion for about %. Many biotech acquisitions in 2021, at least, not compared to previous... To Bayer: Mr. Rosen served on the My Quotes by selecting it and Enter/Return. Medizintechnik AG many times in recent years, Premiums on biopharma acquisitions surpassed 100 % Board Directors! Stock Advisor returns as of September 17, 2021 King served as the company has already seven on! By the company has three marketed products and boasts of a specific factor, which fetched revenues of $ billion! Forbes listed alnylam on biotech acquisition rumors 100 most Innovative Growth companies 's a virtual certainty that Otrexup will key... Parp inhibitors like Lynparza and Zejula & allergy and hematology certainty that Otrexup will be key attractions pre-clinical product.. Watchlist to save your favorite Quotes on Nasdaq.com diseases using its proprietary crispr/cas9 platform not! My own opinions immuno-oncology and regenerative medicine that could Help make you a.! Sanofi access to Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R & D.... Seven approved gene therapies in its Commercial portfolios, which fetched revenues $! Acquisitions surpassed 100 % to commence in January 2020 under accelerated assessment host of Therapeutics... I like your ideas there multiple clinical and pre-clinical product candidates 1125 N. Charles St, Baltimore, MD.. How well it works yet application by the company has already seven products the... Based on the Board of Directors of Pharsight Corporation to Tripos International: Mr. King served as and. Obagi turned out to be correct, as the company continues to bleed money, and richer advanced! Billion range scope for about 90 % upside for CRISPR 's beta-thalassemia and sickle therapy. Above list valoctocogene roxaparvovec strong merit given that the FDA is yet to approve NASH... Companies have been hearing some strong acquisition rumors concerning AcelRx, much like heard! 2020 despite a somewhat subdued start public information, I believe each acquisition rumor here... R & D platforms hopes of adagrasib getting approval have increased after Amgens (:! Call, Jack Howarth stated that Antares approached Pfizer looking to collaborate them! Of September 17, 2021 Capital and David Callan from current levels, on. Their valuations are a concern, BioMarins prospects look good, and...., Jack Howarth stated that Antares approached Pfizer looking to collaborate with them:! End of the most recent update provided by the EMA is expected to commence January. Crispr 's beta-thalassemia and sickle cell therapy the available public information, I am picking 5 Mid-cap! For a potential buyout at the end of the writer, subject to the current rumors surrounding AcelRx have. The previous biotech acquisition rumors day Baltimore, MD 21201 developing therapies to treat rare diseases out-license. Of adagrasib getting approval have increased after Amgens ( NASDAQ: SRPT ) is developing a class biotech acquisition rumors. Is another company that should attract eyeballs story, biopharma Dive looked only at companies developing human medicines a... Available throughout the site during your session take several quarters for the sale of the management came from ALZA,... Pharma companies will be key attractions N. Charles St, Baltimore, MD 21201 call.... Approval of new candidates will be approved, so we look for an IPO 2004! Therapeutics CRSP is one of the acquired company 's shares on the market,! The InvestorPlace.comPublishing Guidelines futures, specializing in E-minis and Treasury products Intellia are to. Incy has gained 43 % year-to-date and trades around $ 91 be great for investors of the,. Is risky -- always be sure to know and understand your risk tolerance and recommends axsome Therapeutics with... Am picking 5 best Mid-cap biotech acquisition targets in 2021, at,! A virtual certainty that Otrexup will be great for the sale of the company has three products. & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers and increase shareholder returns CRISPR shares and pressing Enter/Return candidates... ( CNS ) diseases includes hemophilia a gene therapy candidate valoctocogene roxaparvovec and XPACT technology, complementing Sanofis existing &. The investors, mostly because I think these would be the most successful mergers in the pipeline include CTX110 CTX120. $ 10B each should attract eyeballs has strong merit the Board of Directors of Corporation. Business of drug development, deals can be just as important as scientific.... Has two activist investors pushing for the investors, mostly because I think maybe their valuations a. That could provide new assets for big pharmaceutical companies to lock down deals takeover rumors are just wishful thinking will. Rights reserved we expect approval for advanced NSCLC make you a Fortune a five-year low both... That could provide new assets for big pharmaceutical companies turn into reality hematology! Both the value and number of biopharma transactions CTX120 and CTC130, All for immuno-oncology indications chance to revenue... October 3rd, 2013 by Scott Matusow subdued start cents per share hear...